12:58:07 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-18 15-10 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-06 Ordinarie utdelning MODU 0.00 EUR
2024-04-26 15-10 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-10-20 15-10 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-03 Ordinarie utdelning MODU 0.00 EUR
2023-05-02 Årsstämma 2024
2023-04-28 15-10 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-03 Ordinarie utdelning MODU 0.00 EUR
2022-05-02 Årsstämma 2022

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Modulight är verksamt inom teknikbranschen. Bolaget designar, marknadsför och producerar biomedicinska laserprodukter som används inom onkologi, genetik och oftalmologi. Kunderna består primärt av sjukhus och företagskunder verksamma inom medicinteknik. Utöver huvudverksamheten erbjuds även diverse mervärdestjänster. Störst verksamhet återfinns inom Europa.
2022-04-20 06:30:00

MODULIGHT CORPORATION, COMPANY RELEASE, INSIDER INFORMATION, 20 APRIL, 2022, AT 07.30 A.M. FINNISH TIME
 
Modulight Corporation has received a purchase order from an existing neurology customer today on April 20, 2022. This customer’s application is in the field of diagnostics, while Modulight has already other customers using the same technology for treatment of brain cancer. The customer is a private US company.
 
The total value of the order is 3.9 million US dollars (approx. EUR 3.6 million). Monthly deliveries are planned for the period 3Q22 – 2Q23 and the order is recognized as revenue based on the deliveries during this period.
 
“This purchase order is a good example of Modulight’s deep co-operation with its customers in their product development projects. At an earlier stage, we tailored our product based on customer’s application requirements, and now they are moving forward to the next phase in their commercialization path. That said, this is not yet commercial production. This project provides us with experience that we could utilize in other biomedical projects”, comments Seppo Orsila, the CEO of Modulight.
 
Modulight is currently on its silent period and will publish it’s 1Q22 results on 28 April, 2022. 
 
For further information, please contact:
CEO: Seppo Orsila, m. +358 40 830 4671 
IR: Ulla Haapanen m. +358 40 830 4676
Email: ir@modulight.com
 
Certified Adviser: Danske Bank A/S, Finland Branch, m. +358 40 414 5358
 
www.modulight.com
Twitter: @modulight, @orsila

Modulight in brief
 
Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company’s products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight's products are used worldwide by many Fortune 500 companies, international pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.